Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms

Genomic sequential analysis panels and NGS comprehensive genomic profiling (CGP) are covered for solid tumor patients with advanced (stage III/IV), recurrent, relapsed, refractory, or metastatic disease who are candidates for further cancer treatment, subject to clinical specifics (e.g., NSCLC and mCRC criteria). Coverage requires testing be performed in a CLIA-certified laboratory, ordered by the treating physician, not duplicate CGP testing for the same genetic content, and use assays that detect NCCN Category 1/2A genes or meet FDA or validated LDT standards; hematologic malignancies, ctDNA, and germline testing are excluded.

"Genomic sequential analysis panel is covered for newly diagnosed non-small cell lung cancer (NSCLC) patients with advanced stage IIIB or IV disease who are not amenable to resection or radiation wi..."

Sign up to see full coverage criteria, indications, and limitations.